



CORE BRIEF TO MANAGEMENT GROUP MEMBERS

MEETING HELD ON 23 MAY 2019

This briefing sets out the key areas of discussion and decision. It aims to ensure the Management Group members have a common core brief to disseminate within their organisation.

1. Welcome and Introductions

The Chair welcomed members to the meeting.

2. Minutes of the Previous Meeting and Action Log

The minutes of the meeting held on 25 April 2019 were approved subject to minor revisions.

Members noted the action log and received updates on:

- MG086 IVF: Royal Shrewsbury Hospital RTT Escalation - De-escalation will not take place until WHSSC receives consistent information from the provider.
- MG121 Lynch Syndrome - Information not received on business case from CVUHB. Proposal expected to be presented at June meeting.
- MG129 Thomas Report - CN currently drafting WHSSC response.
- MG130 Shrewsbury and Telford NHS Trust - Renal Network has picked up issues and will report back on recommended pathway change.
- MG131 Welsh Language Standards - Work on standard templates carried out by health boards. Changes will not be ready for this year's SLA process.
- MG132 Lynch Syndrome - NHSW Collaborative papers have been circulated.

3. Report from the Managing Director

Members received the Managing Director's report, which included:

- **Cystic Fibrosis - Business Case Update** Assurance had been received around a number of points but further work was required; a consolidated report would be brought back to the next meeting.
- **Hyperbaric Oxygen Therapy (HBOT)** The private provider in Cardiff was reported to be working at a loss but proposed to service south Wales from its Plymouth unit. Members agreed with this proposal. WHSSC to amend contract accordingly to ensure access.
- **Bariatric Surgery** Due to improved performance the service had been taken out of the WHSSC Escalation Process.

- **Implementation of ICP 2019-22** There had been a delay in bringing funding releases to MG during April and May but the majority of these would be presented to the June meeting.
- **Low Dose Rate Brachytherapy for Prostate Cancer** Velindre had reported that it would no longer be providing this service and proposed that patients be referred to Bristol under an outsource arrangement. Subject to due diligence of the Bristol service the proposed transfer was supported in principle. Velindre would, however, be developing a business case for high dose brachytherapy service for prostate cancer patients. This case will need to be considered through the ICP process as a new service. The WHSSC team will investigate whether Bristol are able to provide low dose brachytherapy and will review the commissioning policy in the context of the changing pattern of demand and provision.

4. Major Trauma Network - Presentation

Members received a presentation on establishing the Major Trauma Network for south, mid and west Wales.

5. Implementation of the Revised WHSSC Policy Proposal for Cochlear Implants for Children and Adults with Severe to Profound Deafness

Members received a paper on the implementation of the revised WHSSC policy proposal for cochlear implants for children and adults with severe to profound deafness.

Members resolved to approve the recommendation and noted the pressure on the NICE contingency budget.

6. Tertiary Cardiology - Commissioning a Complex Device service at Aneurin Bevan University Health Board

Members received a paper on the proposed commissioning of a tertiary cardiology complex device service at Aneurin Bevan University Health Board for its resident population.

Members resolved to approve the recommendation subject to receipt of assurance that the service is meeting the standards for implanting.

7. Inherited Bleeding Disorders – Request for Funding Release

Members received a paper that requested approval for the release of funding to implement the Integrated Commissioning Plan scheme 19/280 Inherited Bleeding Disorders: south Wales.

Members approved the request, subject to assurances around equity for PTHB patients accessing care from English providers via the implementation of a standard service specification.

8. Predicting the future impact of Advanced Therapeutic Medicinal Products (ATMPs) in NHS Wales

Members received the paper which provided an overview of the work done to date by the WHSS Team. This work would be progressed further and has been shared with Welsh Government, receiving positive feedback.

9. Tier 4 Specialist Perinatal Mental Health in Wales

Members were advised that a paper was due to come to Management Group but was not yet ready.

10. WHSSC Policy Group: Update

Members received a paper on the work of the WHSSC Policy Group and noted the information presented within the report.

11. Integrated Performance Report

Members received a report that provided a summary of the performance of services commissioned by WHSSC for March 2019 and noted the actions being undertaken to address areas of non-compliance.

12. Finance Report 2019-20 Month 1

Members received a report that set out the financial position for WHSSC for the first month of 2019-20, being an underspend of £112k. Members received an update from the Director of Finance on the agreed position in respect of cross border contracting flows and that this will require further funding from health boards equivalent to 2% of cross border baselines. WHSSC will share the final impact assessment.

